Eliot Finkel Investment Counsel LLC cut its position in Pfizer Inc. (NYSE:PFE) by 1.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,136 shares of the biopharmaceutical company’s stock after selling 2,500 shares during the quarter. Pfizer accounts for 5.3% of Eliot Finkel Investment Counsel LLC’s holdings, making the stock its 7th largest holding. Eliot Finkel Investment Counsel LLC’s holdings in Pfizer were worth $4,835,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Orser Capital Management LLC grew its stake in shares of Pfizer by 2.7% in the fourth quarter. Orser Capital Management LLC now owns 10,990 shares of the biopharmaceutical company’s stock valued at $428,000 after buying an additional 290 shares in the last quarter. S.E.E.D. Planning Group LLC acquired a new position in Pfizer during the 4th quarter worth $479,000. Koshinski Asset Management Inc. grew its stake in Pfizer by 66.4% during the 4th quarter. Koshinski Asset Management Inc. now owns 25,985 shares of the biopharmaceutical company’s stock worth $1,011,000 after purchasing an additional 10,373 shares in the last quarter. Certified Advisory Corp grew its stake in Pfizer by 37.4% during the 4th quarter. Certified Advisory Corp now owns 44,760 shares of the biopharmaceutical company’s stock worth $1,754,000 after purchasing an additional 12,194 shares in the last quarter. Finally, Stratos Wealth Partners LTD. grew its stake in Pfizer by 1.2% during the 4th quarter. Stratos Wealth Partners LTD. now owns 171,888 shares of the biopharmaceutical company’s stock worth $6,735,000 after purchasing an additional 2,040 shares in the last quarter. 70.28% of the stock is owned by institutional investors and hedge funds.

Several research firms recently commented on PFE. Cantor Fitzgerald reissued a “buy” rating and set a $53.00 target price on shares of Pfizer in a research note on Thursday, March 19th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target for the company. in a report on Monday, May 4th. JPMorgan Chase & Co. decreased their price target on Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Monday. Morgan Stanley decreased their price target on Pfizer from $43.00 to $36.00 and set an “equal weight” rating for the company in a report on Thursday, April 2nd. Finally, Standpoint Research raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $41.19.

In related news, EVP Douglas M. Lankler sold 65,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total value of $2,460,250.00. Following the transaction, the executive vice president now owns 135,375 shares in the company, valued at approximately $5,123,943.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jennifer B. Damico sold 2,181 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $38.35, for a total value of $83,641.35. Following the completion of the transaction, the senior vice president now owns 9,647 shares in the company, valued at approximately $369,962.45. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by insiders.

Shares of Pfizer stock traded down $2.59 on Monday, hitting $35.60. The stock had a trading volume of 3,596,432 shares, compared to its average volume of 21,453,034. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $44.56. The company has a current ratio of 1.02, a quick ratio of 0.78 and a debt-to-equity ratio of 0.56. The stock has a market cap of $212.14 billion, a price-to-earnings ratio of 12.51, a P/E/G ratio of 2.79 and a beta of 0.70. The company’s 50 day moving average price is $37.10 and its 200 day moving average price is $36.82.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.09. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The business had revenue of $12.03 billion during the quarter, compared to the consensus estimate of $11.38 billion. During the same period in the previous year, the business earned $0.85 EPS. The business’s quarterly revenue was down 8.3% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.8 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 8th will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 4.27%. The ex-dividend date of this dividend is Thursday, May 7th. Pfizer’s payout ratio is currently 51.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: After-Hours Trading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.